Ibudilast, a pharmacologic phosphodiesterase inhibitor, prevents human immunodeficiency virus-1 tat-mediated activation of microglial cells

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Kiebala, Michelle ^a   Maggirwar, Sanjay B ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2A RECEPTOR; I KAPPA B ALPHA; IBUDILAST; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHOPROTEIN PHOSPHATASE; SERINE THREONINE PROTEIN PHOSPHATASE; TRANSACTIVATOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AUTACOID; PHOSPHODIESTERASE INHIBITOR; PYRIDINE DERIVATIVE;

ANIMAL CELL; ARTICLE; CELL ACTIVATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; INHIBITION KINETICS; MICROGLIA; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; ANIMAL; BIOSYNTHESIS; DRUG EFFECT; ENZYMOLOGY; GENETIC TRANSCRIPTION; GENETICS; METABOLISM;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANIMALS; ENZYME ACTIVATION; HIV-1; HUMANS; INFLAMMATION MEDIATORS; MICE; MICROGLIA; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHODIESTERASE INHIBITORS; PHOSPHOPROTEIN PHOSPHATASES; PYRIDINES; RECEPTOR, ADENOSINE A2A; SIGNAL TRANSDUCTION; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79954523511     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0018633     Document Type: Article

References (96)

1. Resnick L, Berger JR, Shapshak P, Tourtellotte WW, (1988) Early penetration of the blood-brain-barrier by HIV. Neurology 38: 9-14.
2. Kaul M, Lipton SA, (2006) Mechanisms of neuronal injury and death in HIV-1 associated dementia. Curr HIV Res 4: 307-318.
3. Nath A, Sacktor N, (2006) Influence of highly active antiretroviral therapy on persistence of HIV in the central nervous system. Curr Opin Neurol 19: 358-361.
4. Tozzi V, Balestra P, Bellagamba R, Corpolongo A, Salvatori MF, et al. (2007) Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr 45: 174-182.
5. McArthur JC, (2004) HIV dementia: an evolving disease. J Neuroimmunol 157: 3-10.
6. Archibald SL, Masliah E, Fennema-Notestine C, Marcotte TD, Ellis RJ, et al. (2004) Correlation of in vivo neuroimaging abnormalities with postmortem human immunodeficiency virus encephalitis and dendritic loss. Arch Neurol 61: 369-376.
7. Bissel SJ, Wang G, Ghosh M, Reinhart TA, Capuano S 3rd, et al. (2002) Macrophages relate presynaptic and postsynaptic damage in simian immunodeficiency virus encephalitis. Am J Pathol 160: 927-941.
8. Everall IP, Heaton RK, Marcotte TD, Ellis RJ, McCutchan JA, et al. (1999) Cortical synaptic density is reduced in mild to moderate human immunodeficiency virus neurocognitive disorder. HNRC Group. HIV Neurobehavioral Research Center. Brain Pathol 9: 209-217.
9. Masliah E, Heaton RK, Marcotte TD, Ellis RJ, Wiley CA, et al. (1997) Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center. Ann Neurol 42: 963-972.
10. Major EO, (2009) Progressive Multifocal Leukoencephalopathy in Patients on Immunomodulatory Therapies. Annu Rev Med.
11. Cardenas V, Meyerhoff D, Studholme C, Kornak J, Rothlind J, et al. (2009) Evidence for ongoing brain injury in human immunodeficiency virus-positive patients treated with antiretroviral therapy. J Neurovirol pp. 1-10.
12. Chen Y, An H, Zhu H, Stone T, Smith JK, et al. (2009) White matter abnormalities revealed by diffusion tensor imaging in non-demented and demented HIV+ patients. Neuroimage 47: 1154-1162.
13. Gongvatana A, Schweinsburg BC, Taylor MJ, Theilmann RJ, Letendre SL, et al. (2009) White matter tract injury and cognitive impairment in human immunodeficiency virus-infected individuals. J Neurovirol 15: 187-195.
14. Langford TD, Letendre SL, Marcotte TD, Ellis RJ, McCutchan JA, et al. (2002) Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy. AIDS 16: 1019-1029.
15. Langford TD, Letendre SL, Larrea GJ, Masliah E, (2003) Changing patterns in the neuropathogenesis of HIV during the HAART era. Brain Pathol 13: 195-210.
16. Avison MJ, Nath A, Greene-Avison R, Schmitt FA, Bales RA, et al. (2004) Inflammatory changes and breakdown of microvascular integrity in early human immunodeficiency virus dementia. J Neurovirol 10: 223-232.
17. Glass JD, Fedor H, Wesselingh SL, McArthur JC, (1995) Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann Neurol 38: 755-762.
18. Everall IP, Glass JD, McArthur J, Spargo E, Lantos P, (1994) Neuronal density in the superior frontal and temporal gyri does not correlate with the degree of human immunodeficiency virus-associated dementia. Acta Neuropathol 88: 538-544.
19. Rumbaugh JA, Nath A, (2006) Developments in HIV neuropathogenesis. Curr Pharm Des 12: 1023-1044.
20. Westendorp MO, Frank R, Ochsenbauer C, Stricker K, Dhein J, et al. (1995) Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature 375: 497-500.
21. Xiao H, Neuveut C, Tiffany HL, Benkirane M, Rich EA, et al. (2000) Selective CXCR4 antagonism by Tat: implications for in vivo expansion of coreceptor use by HIV-1. Proc Natl Acad Sci U S A 97: 11466-11471.
22. Hayashi K, Pu H, Andras IE, Eum SY, Yamauchi A, et al. (2006) HIV-TAT protein upregulates expression of multidrug resistance protein 1 in the blood-brain barrier. J Cereb Blood Flow Metab 26: 1052-1065.
23. D'Aversa TG, Yu KO, Berman JW, (2004) Expression of chemokines by human fetal microglia after treatment with the human immunodeficiency virus type 1 protein Tat. J Neurovirol 10: 86-97.
24. Eugenin EA, Dyer G, Calderon TM, Berman JW, (2005) HIV-1 tat protein induces a migratory phenotype in human fetal microglia by a CCL2 (MCP-1)-dependent mechanism: possible role in NeuroAIDS. Glia 49: 501-510.
25. Schifitto G, Zhang J, Evans SR, Sacktor N, Simpson D, et al. (2007) A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. Neurology 69: 1314-1321.
26. Schifitto G, Yiannoutsos CT, Ernst T, Navia BA, Nath A, et al. (2009) Selegiline and oxidative stress in HIV-associated cognitive impairment. Neurology 73: 1975-1981.
27. Schifitto G, Navia BA, Yiannoutsos CT, Marra CM, Chang L, et al. (2007) Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. Aids 21: 1877-1886.
28. Rolan P, Hutchinson M, Johnson K, (2009) Ibudilast: a review of its pharmacology, efficacy and safety in respiratory and neurological disease. Expert Opin Pharmacother 10: 2897-2904.
29. Ledeboer A, Hutchinson MR, Watkins LR, Johnson KW, (2007) Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. Expert Opin Investig Drugs 16: 935-950.
30. Ledeboer A, Liu T, Shumilla JA, Mahoney JH, Vijay S, et al. (2006) The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic pain. Neuron Glia Biol 2: 279-291.
31. Deree J, Martins JO, Melbostad H, Loomis WH, Coimbra R, (2008) Insights into the regulation of TNF-alpha production in human mononuclear cells: the effects of non-specific phosphodiesterase inhibition. Clinics (Sao Paulo) 63: 321-328.
32. Suzumura A, Ito A, Yoshikawa M, Sawada M, (1999) Ibudilast suppresses TNFalpha production by glial cells functioning mainly as type III phosphodiesterase inhibitor in the CNS. Brain Res 837: 203-212.
33. Barkhof F, Hulst HE, Drulovic J, Uitdehaag BM, Matsuda K, et al. (2010) Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant? Neurology 74: 1033-1040.
34. Beardsley PM, Shelton KL, Hendrick E, Johnson KW, (2010) The glial cell modulator and phosphodiesterase inhibitor, AV411 (ibudilast), attenuates prime- and stress-induced methamphetamine relapse. Eur J Pharmacol 637: 102-108.
35. Navarro J, Punzon C, Jimenez JL, Fernandez-Cruz E, Pizarro A, et al. (1998) Inhibition of phosphodiesterase type IV suppresses human immunodeficiency virus type 1 replication and cytokine production in primary T cells: involvement of NF-kappaB and NFAT. J Virol 72: 4712-4720.
36. Dezube BJ, Lederman MM, Spritzler JG, Chapman B, Korvick JA, et al. (1995) High-dose pentoxifylline in patients with AIDS: inhibition of tumor necrosis factor production. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. J Infect Dis 171: 1628-1632.
37. Angel JB, Saget BM, Walsh SP, Greten TF, Dinarello CA, et al. (1995) Rolipram, a specific type IV phosphodiesterase inhibitor, is a potent inhibitor of HIV-1 replication. Aids 9: 1137-1144.
38. Chang HC, Samaniego F, Nair BC, Buonaguro L, Ensoli B, (1997) HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. Aids 11: 1421-1431.
39. Nath A, Haughey NJ, Jones M, Anderson C, Bell JE, et al. (2000) Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine. Ann Neurol 47: 186-194.
40. Nichol KE, Poon WW, Parachikova AI, Cribbs DH, Glabe CG, et al. (2008) Exercise alters the immune profile in Tg2576 Alzheimer mice toward a response coincident with improved cognitive performance and decreased amyloid. J Neuroinflammation 5: 13.
41. de Jager W, te Velthuis H, Prakken BJ, Kuis W, Rijkers GT, (2003) Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol 10: 133-139.
42. Yoshikawa M, Suzumura A, Tamaru T, Takayanagi T, Sawada M, (1999) Effects of phosphodiesterase inhibitors on cytokine production by microglia. Mult Scler 5: 126-133.
43. Frankel AD, Pabo CO, (1988) Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55: 1189-1193.
44. Gonzalez-Scarano F, Martin-Garcia J, (2005) The neuropathogenesis of AIDS. Nat Rev Immunol 5: 69-81.
45. Saha RN, Pahan K, (2003) Tumor necrosis factor-alpha at the crossroads of neuronal life and death during HIV-associated dementia. J Neurochem 86: 1057-1071.
46. Mengozzi M, De Filippi C, Transidico P, Biswas P, Cota M, et al. (1999) Human immunodeficiency virus replication induces monocyte chemotactic protein-1 in human macrophages and U937 promonocytic cells. Blood 93: 1851-1857.
47. Zen K, Masuda J, Sasaguri T, Kosaka C, Ogata J, (1994) Gene expression of monocyte chemoattractant protein-1 in human monocytes is regulated by cell density through protein tyrosine kinase and protein kinase C. Exp Cell Res 215: 172-179.
48. Turchan-Cholewo J, Dimayuga FO, Gupta S, Keller JN, Knapp PE, et al. (2009) Morphine and HIV-Tat increase microglial-free radical production and oxidative stress: possible role in cytokine regulation. J Neurochem 108: 202-215.
49. Turchan-Cholewo J, Dimayuga VM, Gupta S, Gorospe RM, Keller JN, et al. (2009) NADPH oxidase drives cytokine and neurotoxin release from microglia and macrophages in response to HIV-Tat. Antioxid Redox Signal 11: 193-204.
50. Henn A, Lund S, Hedtjarn M, Schrattenholz A, Porzgen P, et al. (2009) The suitability of BV2 cells as alternative model system for primary microglia cultures or for animal experiments examining brain inflammation. ALTEX 26: 83-94.
51. Oh YT, Lee JY, Lee J, Lee JH, Kim JE, et al. (2010) Oleamide suppresses lipopolysaccharide-induced expression of iNOS and COX-2 through inhibition of NF-kappaB activation in BV2 murine microglial cells. Neurosci Lett 474: 148-153.
52. Jung WK, Lee DY, Park C, Choi YH, Choi I, et al. (2010) Cilostazol is anti-inflammatory in BV2 microglial cells by inactivating nuclear factor-kappaB and inhibiting mitogen-activated protein kinases. Br J Pharmacol 159: 1274-1285.
53. Bokhari SM, Yao H, Bethel-Brown C, Fuwang P, Williams R, et al. (2009) Morphine enhances Tat-induced activation in murine microglia. J Neurovirol 15: 219-228.
54. Sui Z, Sniderhan LF, Schifitto G, Phipps RP, Gelbard HA, et al. (2007) Functional synergy between CD40 ligand and HIV-1 Tat contributes to inflammation: implications in HIV type 1 dementia. J Immunol 178: 3226-3236.
55. Kreth S, Ledderose C, Luchting B, Weis F, Thiel M, (2010) Immunomodulatory properties of pentoxifylline are mediated via adenosine-dependent pathways. Shock 34: 10-16.
56. Yasui K, Agematsu K, Shinozaki K, Hokibara S, Nagumo H, et al. (2000) Theophylline induces neutrophil apoptosis through adenosine A2A receptor antagonism. J Leukoc Biol 67: 529-535.
57. Yasui K, Kondo Y, Wada T, Yashiro M, Tsuge M, et al. (2009) Theophylline inhibits the differentiation of human monocyte into dendritic cell potentially via adenosine receptor antagonism. Clin Exp Allergy 39: 1857-1865.
58. Hasko G, Kuhel DG, Chen JF, Schwarzschild MA, Deitch EA, et al. (2000) Adenosine inhibits IL-12 and TNF-[alpha] production via adenosine A2a receptor-dependent and independent mechanisms. FASEB J 14: 2065-2074.
59. Mayne M, Fotheringham J, Yan HJ, Power C, Del Bigio MR, et al. (2001) Adenosine A2A receptor activation reduces proinflammatory events and decreases cell death following intracerebral hemorrhage. Ann Neurol 49: 727-735.
60. McWhinney CD, Dudley MW, Bowlin TL, Peet NP, Schook L, et al. (1996) Activation of adenosine A3 receptors on macrophages inhibits tumor necrosis factor-alpha. Eur J Pharmacol 310: 209-216.
61. Fotheringham J, Mayne M, Holden C, Nath A, Geiger JD, (2004) Adenosine receptors control HIV-1 Tat-induced inflammatory responses through protein phosphatase. Virology 327: 186-195.
62. Zarubin T, Han J, (2005) Activation and signaling of the p38 MAP kinase pathway. Cell Res 15: 11-18.
63. Costantini TW, Deree J, Martins JO, Loomis WH, Bansal V, et al. (2010) Pentoxifylline attenuates leukoreduced stored blood-induced neutrophil activation through inhibition of mitogen-activated protein kinases. Immunopharmacol Immunotoxicol 32: 74-81.
64. Moon EY, Lerner A, (2003) PDE4 inhibitors activate a mitochondrial apoptotic pathway in chronic lymphocytic leukemia cells that is regulated by protein phosphatase 2A. Blood 101: 4122-4130.
65. Sandoval J, Escobar J, Pereda J, Sacilotto N, Rodriguez JL, et al. (2009) Pentoxifylline prevents loss of PP2A phosphatase activity and recruitment of histone acetyltransferases to proinflammatory genes in acute pancreatitis. J Pharmacol Exp Ther 331: 609-617.
66. Cyert MS, (2001) Regulation of nuclear localization during signaling. J Biol Chem 276: 20805-20808.
67. Israel A, (1995) A role for phosphorylation and degradation in the control of NF-kappa B activity. Trends Genet 11: 203-205.
68. Sun W, Wang H, Zhao X, Yu Y, Fan Y, et al. (2010) Protein phosphatase 2A acts as a mitogen-activated protein kinase kinase kinase 3 (MEKK3) phosphatase to inhibit lysophosphatidic acid-induced IkappaB kinase beta/nuclear factor-kappaB activation. J Biol Chem 285: 21341-21348.
69. Nath A, Conant K, Chen P, Scott C, Major EO, (1999) Transient exposure to HIV-1 Tat protein results in cytokine production in macrophages and astrocytes. A hit and run phenomenon. J Biol Chem 274: 17098-17102.
70. Sun SC, Maggirwar SB, Harhaj E, (1995) Activation of NF-kappa B by phosphatase inhibitors involves the phosphorylation of I kappa B alpha at phosphatase 2A-sensitive sites. J Biol Chem 270: 18347-18351.
71. Sui Z, Sniderhan LF, Fan S, Kazmierczak K, Reisinger E, et al. (2006) Human immunodeficiency virus-encoded Tat activates glycogen synthase kinase-3beta to antagonize nuclear factor-kappaB survival pathway in neurons. Eur J Neurosci 23: 2623-2634.
72. Ghosh S, Karin M, (2002) Missing pieces in the NF-kappaB puzzle. Cell 109 (Suppl): S81-96.
73. Karin M, Ben-Neriah Y, (2000) Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 18: 621-663.
74. Kovacs AD, Chakraborty-Sett S, Ramirez SH, Sniderhan LF, Williamson AL, et al. (2004) Mechanism of NF-kappaB inactivation induced by survival signal withdrawal in cerebellar granule neurons. Eur J Neurosci 20: 345-352.
75. Fine SM, Maggirwar SB, Elliott PR, Epstein LG, Gelbard HA, et al. (1999) Proteasome blockers inhibit TNF-alpha release by lipopolysaccharide stimulated macrophages and microglia: implications for HIV-1 dementia. J Neuroimmunol 95: 55-64.
76. Huang B, Yang XD, Lamb A, Chen LF, (2010) Posttranslational modifications of NF-kappaB: another layer of regulation for NF-kappaB signaling pathway. Cell Signal 22: 1282-1290.
77. Leghmari K, Bennasser Y, Bahraoui E, (2008) HIV-1 Tat protein induces IL-10 production in monocytes by classical and alternative NF-kappaB pathways. Eur J Cell Biol 87: 947-962.
78. Kiebala M, Polesskaya O, Yao Z, Perry SW, Maggirwar SB, (2010) Nuclear Factor-Kappa B Family Member RelB Inhibits Human Immunodeficiency Virus-1 Tat-Induced Tumor Necrosis Factor-Alpha Production. PLoS One 5: e11875.
79. Vermeulen L, De Wilde G, Van Damme P, Vanden Berghe W, Haegeman G, (2003) Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). Embo J 22: 1313-1324.
80. Fine SM, Angel RA, Perry SW, Epstein LG, Rothstein JD, et al. (1996) Tumor necrosis factor alpha inhibits glutamate uptake by primary human astrocytes. Implications for pathogenesis of HIV-1 dementia. J Biol Chem 271: 15303-15306.
81. Gelbard HA, Dzenko KA, DiLoreto D, del Cerro C, del Cerro M, et al. (1993) Neurotoxic effects of tumor necrosis factor alpha in primary human neuronal cultures are mediated by activation of the glutamate AMPA receptor subtype: implications for AIDS neuropathogenesis. Dev Neurosci 15: 417-422.
82. Brabers NA, Nottet HS, (2006) Role of the pro-inflammatory cytokines TNF-alpha and IL-1beta in HIV-associated dementia. Eur J Clin Invest 36: 447-458.
83. Rumbaugh JA, Steiner J, Sacktor N, Nath A, (2008) Developing neuroprotective strategies for treatment of HIV-associated neurocognitive dysfunction. Futur HIV Ther 2: 271-280.
84. Cherry CL, McArthur JC, Hoy JF, Wesselingh SL, (2003) Nucleoside analogues and neuropathy in the era of HAART. J Clin Virol 26: 195-207.
85. Vidal F, Gutierrez F, Gutierrez M, Olona M, Sanchez V, et al. (2010) Pharmacogenetics of adverse effects due to antiretroviral drugs. AIDS Rev 12: 15-30.
86. Neuner P, Klosner G, Schauer E, Pourmojib M, Macheiner W, et al. (1994) Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells. Immunology 83: 262-267.
87. Heijligenberg R, Romijn JA, Ackermans M, Endert E, Timmer JG, et al. (1998) The maximal tolerable intravenous dosage of pentoxifylline in AIDS patients does not inhibit lipopolysaccharide-stimulated tumor necrosis factor alpha production. AIDS Res Hum Retroviruses 14: 299-303.
88. Coimbra R, Melbostad H, Loomis W, Tobar M, Hoyt DB, (2005) Phosphodiesterase inhibition decreases nuclear factor-kappaB activation and shifts the cytokine response toward anti-inflammatory activity in acute endotoxemia. J Trauma 59: 575-582.
89. Coimbra R, Melbostad H, Loomis W, Porcides RD, Wolf P, et al. (2006) LPS-induced acute lung injury is attenuated by phosphodiesterase inhibition: effects on proinflammatory mediators, metalloproteinases, NF-kappaB, and ICAM-1 expression. J Trauma 60: 115-125.
90. Ji Q, Zhang L, Lv R, Jia H, Xu J, (2006) Pentoxifylline decreases up-regulated nuclear factor kappa B activation and cytokine production in the rat retina following transient ischemia. Ophthalmologica 220: 217-224.
91. Ollivier V, Parry GC, Cobb RR, de Prost D, Mackman N, (1996) Elevated cyclic AMP inhibits NF-kappaB-mediated transcription in human monocytic cells and endothelial cells. J Biol Chem 271: 20828-20835.
92. Gilmore TD, Herscovitch M, (2006) Inhibitors of NF-kappaB signaling: 785 and counting. Oncogene 25: 6887-6899.
93. Meffert MK, Baltimore D, (2005) Physiological functions for brain NF-kappaB. Trends Neurosci 28: 37-43.
94. Perry SW, Dewhurst S, Bellizzi MJ, Gelbard HA, (2002) Tumor necrosis factor-alpha in normal and diseased brain: Conflicting effects via intraneuronal receptor crosstalk? J Neurovirol 8: 611-624.
95. Wong M, Ziring D, Korin Y, Desai S, Kim S, et al. (2008) TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol 126: 121-136.
96. Lysandropoulos AP, Du Pasquier RA, (2010) Demyelination as a complication of new immunomodulatory treatments. Curr Opin Neurol 23: 226-233.